OraSure (OSUR) Q4 2025 earnings review
Revenue Stabilizes, But the Turnaround Hinges on the FDA
OraSure survived its 2025 'transition year,' but the financial toll is stark. Q4 revenue fell 29% YoY to $26.8M, and operating cash flow reversed from a $27M inflow in 2024 to a $49M burn in 2025. While management insists 2026 will mark a return to growth, Q1 guidance implies another 8% YoY revenue decline. The entire bull case now sits on the FDA's desk. With submissions for the Sherlock CT/NG self-test and the Colli-Pee collection device filed in December, OraSure is attempting a critical pivot to higher-margin molecular diagnostics. The $199M cash pile provides a comfortable buffer, but until these new products launch, the core business remains stable at a heavily depressed baseline.
🐂 Bull Case
The company successfully submitted its Sherlock CT/NG rapid molecular self-test and Colli-Pee urine collection device to the FDA in December 2025. These unlock massive TAMs ($1.5B and $500M respectively) and represent the future growth engine.
Despite a 29% drop in YoY revenue, Q4 Non-GAAP gross margin improved to 41.4% from 40.1% a year ago. This proves that consolidating the manufacturing footprint to Pennsylvania successfully protected profitability against severe volume deleverage.
🐻 Bear Case
Operating cash flow turned violently negative in 2025, burning $49M compared to generating $27M in 2024. R&D spending to fuel the clinical trials is eroding the cash pile faster than legacy products can replenish it.
The Sample Management Solutions (SMS) segment fell 39% YoY. Management has yet to replace the massive volume lost from a large consumer genomics customer earlier in the year.
⚖️ Verdict: ⚪
Neutral. The company has $199M in cash and zero debt, removing immediate existential risk. However, the massive cash burn and total reliance on pending FDA approvals make this a 'show me' story. The legacy business is too weak to support the stock on its own.
Key Themes
FDA Submissions Unlock Molecular Pipeline
The future of OraSure relies on its technology transition. In December 2025, the company filed FDA submissions for its Colli-Pee at-home urine collection device (for STIs) and the Sherlock rapid molecular self-test for Chlamydia and Gonorrhoeae. These submissions mark a critical pivot from legacy infectious disease tests to high-value, decentralized molecular diagnostics. Approval is the primary catalyst for 2026.
Narrative vs. Reality: The Growth Delay
Management's primary narrative is that OTI is 'positioned to return to growth in 2026.' However, specific guidance contradicts an immediate turnaround. The Q1 2026 revenue guidance midpoint of $27.5M implies an 8% YoY decline (Decelerating). If 2026 is truly a growth year, it will be entirely back-half loaded and heavily dependent on unapproved products, carrying significant execution risk.
Sample Management Remains a Heavy Drag
The Sample Management Solutions segment is Decelerating sharply, down 39% YoY to $9.1M in Q4. The loss of a major consumer genomics customer earlier in 2025 continues to suppress the top line, proving that diversification efforts into clinical and pharma channels have not yet offset the historical concentration risk.
Macro Public Health Headwinds Persist
The macro funding environment remains a severe drag. Diagnostics revenue fell 20% YoY to $15.1M, primarily driven by lower HIV test volumes as public health customers navigate ongoing budget uncertainty and funding freezes (such as PEPFAR/USAID issues flagged in prior quarters). While management notes 'increasing signs of stability,' the actual reported numbers show demand remains weak.
Cash Burn Accelerating Driven by R&D
R&D expenses Reversing aggressively upward is a dual-edged sword. Q4 R&D hit $11.4M, an 87% YoY increase, as the company funded the Sherlock clinical trials. While necessary for the pipeline, this drove the Q4 Operating Loss to $20.1M. Management must prove this spending will step down post-FDA submission, or the $199M cash runway will shrink faster than anticipated.
Gross Margin Resilience
Despite a massive volume deleverage in 2025, Non-GAAP gross margins remained Stable. The company posted 41.4% in Q4, slightly better than the 40.1% a year ago. This highlights the effectiveness of the company's operational restructuring, specifically closing four global sites and insourcing manufacturing to Pennsylvania.
Disciplined Capital Returns
Management executed on its capital allocation strategy, deploying $5M in Q4 to repurchase 1.9 million shares. With $199M in cash and no debt, the balance sheet remains a fortress, allowing the company to return capital to shareholders while simultaneously funding expensive clinical trials.
Other KPIs
Reversing violently from a positive $27.4 million generated in FY24. This $76 million swing in cash generation highlights the heavy cost of the transition year and the aggressive R&D investments required to bring the Sherlock platform to the FDA.
Accelerating sharply. This is an 87% YoY increase from $6.1 million in 24Q4. The spike is directly tied to the final push for the Sherlock CT/NG and Colli-Pee clinical trials ahead of their December FDA submissions.
Decelerating from $267.8 million a year ago, but still represents nearly half of the company's market capitalization. The pristine balance sheet (zero debt) is the primary reason the market is tolerating the current operational cash burn.
Guidance
Decelerating. The midpoint of $27.5 million implies an 8% YoY decline from the $29.9 million reported in Q1 2025. This confirms that the promised 'return to growth' will not happen in the first quarter.
Stable compared to the 41.4% achieved in 25Q4. However, it indicates that the company is struggling to make progress toward its historical target of 50% without a meaningful rebound in sales volume.
Key Questions
Growth Timeline Reality
You maintain that OraSure is positioned to return to growth in 2026, yet Q1 guidance implies an 8% YoY decline. Exactly which quarter do you expect YoY revenue growth to turn positive, and is that dependent on the new FDA approvals?
R&D Run-Rate Post-Submissions
R&D spiked to $11.4 million in Q4 to support the Sherlock and Colli-Pee submissions. Now that those are filed, should we expect R&D to step down immediately in Q1, or will it remain elevated to support the rest of the pipeline?
Sample Management Floor
SMS revenue dropped another 39% this quarter. Has the bleeding from the lost consumer genomics customer fully bottomed out, or will this segment continue to be a YoY headwind in the first half of 2026?
FDA Review Timelines
Given the December submissions for both the Sherlock CT/NG test and the Colli-Pee device, what are the realistic statutory timelines you are modeling for potential FDA clearance and commercial launch?